Hydrogel device enables painless transdermal delivery of nucleic acids

Description

Nucleic acid (NA)-based medicine has been a focal point of research over the past two decades and has shown immense promise for both therapeutics and vaccines. The rapid development and deployment of NA-based vaccines during the COVID-19 pandemic underscored their potential. However, the efficient in vivo delivery of these nucleic acids, particularly when cytosolic delivery is required without leaving residual materials in the body, has remained unsolved.